Where can I buy ontx stock?
· What: Shares of Onconova Therapeutics ( ONTX 2.17%), a clinical-stage biopharmaceutical company developing small-molecule drugs to treat cancer, dropped as much as 22% after announcing the interim...
What happened to Onconova (ontx) stock?
· 3 brokerages have issued 1 year price targets for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average, they expect Onconova Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 825.9% from the stock's current price.
Is onontx stock up 45% since the start of the year?
Find the latest Onconova Therapeutics, Inc. (ONTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Will ontx outperform or underperform the S&P 500 over the long term?
ONTX Onconova Therapeutics is falling or rising technical reasons . Technical analysis forecast for Onconova Therapeutics Stock is that its in a downtrend for shortterm, and I will avoid taking a BUY or a LONG trade in this stock. Look for opportunities to sell or SHORT Onconova Therapeutics ONTX at this time. Stock is falling and might fall more.
Will ONTX stock go up?
Onconova Therapeutics Inc (NASDAQ:ONTX) The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +909.17% increase from the last price of 1.09.
Is ONTX stock good?
Zacks' proprietary data indicates that Onconova Therapeutics, Inc. is currently rated as a Zacks Rank 2 and we are expecting an above average return from the ONTX shares relative to the market in the next few months.
Why did ONTX reverse split?
Instead, Onconova's stockholders who otherwise would have been entitled to a fraction of a share will receive a full share of common stock. The reverse stock split is intended primarily to increase the per share bid price of Onconova's common stock and satisfy the NASDAQ Capital Market continued listing requirement.
Did ONTX reverse split?
Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, May 21, 2021.
Is ONTX a buy now?
During the day the stock fluctuated 4.62% from a day low at $1.30 to a day high of $1.36. The price has fallen in 5 of the last 10 days and is down by -7.14% for this period....Predicted Opening Price for Onconova Therapeutics of Monday, May 9, 2022.Fair opening price May 9, 2022Current price$1.32$1.30 (Undervalued)
Is onconova a buy or sell?
Onconova Therapeutics has received a consensus rating of Buy.
What happens in a reverse split shares?
During a reverse stock split, a company cancels its current outstanding stock and distributes new shares to its shareholders in proportion to the number of shares they owned before the reverse split.
What is a 1/15 reverse stock split?
The 1-for-15 reverse stock split will automatically convert 15 current shares of the Company's common stock into one share of common stock. No fractional shares will be issued in connection with the reverse stock split.
What does onconova therapeutics do?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Is Onconova Therapeutics a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are curren...
How has Onconova Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World He...
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 171,900 sha...
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 16th 2022. View our earnings forecast for On...
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($...
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 202...
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 12 month target prices for Onconova Therapeutics' shares. Their forecasts range from $7.00 to $12.00. On average...
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the following people: Steven M. Fruchtman , President, Chief Executive Officer & Director ( Link...
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Annexon (ANNX) , scPharmaceuticals (SCPH) , BriaCell Therapeutics (BCTX) , Nex...
Is Onconova Therapeutics a buy right now?
What stocks does MarketBeat like better than Onconova Therapeutics?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock.
Are investors shorting Onconova Therapeutics?
Wall Street analysts have given Onconova Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Onconova Therapeutics wasn't one of them.
When is Onconova Therapeutics' next earnings date?
Onconova Therapeutics saw a increase in short interest in August. As of August 13th, there was short interest totaling 721,300 shares, an increase of 12.2% from the July 29th total of 642,600 shares. Based on an average trading volume of 653,000 shares, the days-to-cover ratio is currently 1.1 days.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.#N#View our earnings forecast for Onconova Therapeutics.
How has Onconova Therapeutics' stock price been impacted by COVID-19?
Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its quarterly earnings results on Thursday, August, 12th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.01.
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics' stock was trading at $5.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONTX shares have decreased by 5.0% and is now trading at $5.13.#N#View which stocks have been most impacted by COVID-19.
What is Onconova Therapeutics?
Onconova Therapeutics's stock reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021.
How much is research and development expense for the first quarter of 2021?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
How much cash is in the first quarter of 2021?
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020.
How much is research and development in 2021?
First Quarter Financial Results Cash and cash equivalents as of March 31, 2021 were $48.0 million, compared with $19.0 million as of December 31, 2020. The Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than 18 months.
A Closer Look at ONTX Stock
Research and development expenses were $1.9 million for the first quarter of 2021, compared with $3.4 million for the first quarter of 2020. The decrease was primarily related to lower expenses for the oral rigosertib combination program and the completed Phase 3 INSPIRE study in the 2021 period.
Non-Compliance Issue
One fact that immediately stands out to me is that ONTX stock’s trailing 12-month earnings per share is a loss of around 14 cents.
Making Steady Progress
Unfortunately, in October, Onconova received a letter from the Nasdaq Capital Market bearing bad news.
The Bottom Line
As I alluded to earlier, Onconova specializes in developing products for patients with cancer. The company has three product programs in the pipeline:
1 ONTX Stock's Price Graph & Average Annual Return
Onconova’s progress in advancing its anti-cancer clinical programs is certainly encouraging.
2 How Onconova Therapeutics Inc (ONTX) Stock Performed Against The Entire Stock Market
Below is a graph showing closing prices of Onconova Therapeutics Inc (ONTX) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
4 10 Biggest One-Day Losses
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
Conclusion
Let us now see 10 biggest one-day losses of Onconova Therapeutics Inc (ONTX) stock.
Want to become a smart investor?
Hopefully, the above report helps you learn about the past ten-year performance of Onconova Therapeutics Inc (ONTX) shares. Kindly use the sections below to suggest corrections or improvements to the report.
What is Onconova Therapeutics?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
Where is Onconova Therapeutics located?
Onconova Therapeutics is a biopharmaceutical company with a focus on developing new treatments for cancer. Its work includes developing a proprietary chemistry platform that can target cell pathways used by cancer.
What is Onconova Therapeutics?
It operates out of its headquarters in Pennsylvania.
Where is Onconova Therapeutics located?
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company’s product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.